Evidence map›Paper›PMID 39957772›Full record

ArticleThe Lancet regional health. Southeast Asia2024

Estimating the potential health and economic impacts of new tuberculosis vaccines under varying delivery strategies in Delhi and Gujarat, India: a modelling study.

Rebecca A Clark, Allison Portnoy, Chathika K Weerasuriya, Tom Sumner, Roel Bakker, Rebecca C Harris, Kirankumar Rade, Sanjay Kumar Mattoo, Dheeraj Tumu, Nicolas A Menzies and 1 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in The Lancet regional health. Southeast Asia, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

11 authors.

Rebecca A ClarkTB Modelling Group and TB Centre, LSHTM, UK.
Allison PortnoyDepartment of Global Health, Boston University School of Public Health, USA.
Chathika K WeerasuriyaTB Modelling Group and TB Centre, LSHTM, UK.
Tom SumnerTB Modelling Group and TB Centre, LSHTM, UK.
Roel BakkerTB Modelling Group and TB Centre, LSHTM, UK.
Rebecca C HarrisTB Modelling Group and TB Centre, LSHTM, UK.
Kirankumar RadeWorld Health Organization, India.
Sanjay Kumar MattooCentral TB Division, National Tuberculosis Elimination Program, MoHFW Govt of India, New Delhi, India.
Dheeraj TumuWorld Health Organization, India.
Nicolas A MenziesCenter for Health Decision Science, Harvard T.H. Chan School of Public Health, USA.
Richard G WhiteTB Modelling Group and TB Centre, LSHTM, UK.

Funding

Gates Foundation INV-001754World Health Organization 001
6 · The paper itself

Abstract

Background: India has the largest tuberculosis burden, but the all-age prevalence in 2021 ranged from 747/100,000 in Delhi to 137/100,000 in Gujarat. No modelling studies have compared the potential impact of new tuberculosis vaccines in regions with differing disease and infection prevalence. Methods: We used modelling to simulate hypothetical scenarios of introducing M72/AS01 Findings: The hypothetical M72/AS01 Interpretation: Additional trials for both vaccines are underway, which will provide further evidence on the vaccine efficacy and narrow the range of uncertainty on the estimates. Funding: Bill & Melinda Gates Foundation (INV-001754).

Indexed as

Cost-effectivenessHealth economicsIndiaMathematical modellingSubnationalTuberculosisVaccines

Identifiers

PMID39957772
PMCPMC11827003

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.